Kenvue stock, maker of Tylenol, fall 7.47% after Donald Trump’s announcement on autism.

Ads

Kenvue stock, maker of Tylenol, fell 7.47% on the New York Stock Exchange (NUSE) on Monday, September 22, after US President Donald Trump‘s announcement linking autism to the use of Tylenol. Since September 4, when news first emerged that the United States was investigating the use of acetaminophen, Kenvue’s stock have fallen by more than 10%.

Donald Trump stated that the use of acetaminophen, the active ingredient in Tylenol, is not recommended for pregnant women because it increases the risk of autism in the baby. Currently, there is no scientific data or studies that provide evidence to support this link.

Kenvue said in a statement on Sunday (21), that more than a decade of research, validated by medical and regulatory authorities, confirms there is no scientific basis for this link.